ABSTRACT
Pagefs Disease __________________ • 40 mg/d for 6 months___________________________________________ Risedronate Treatment and Prevention o f Postmenopausal Osteoporosis
or Glucocorticoid-Induced Osteoporosis • 5 mg orally daily or 35 mg weekly Pagefs Disease
__________________ • 30 mg orally once daily for 2 months______________________________ Ibandronate • 2.5 mg orally daily or 150 mg orally once monthly or Sodium__________ • 3 mg IV every 3 months_________________________________________ Etidronate Pagefs Disease Disodium • 5 mg/kg/d to 10 mg/kg/d for a period not to exceed 6 months or
11 mg/kg/d to 20 mg/kg/d for no longer than 3 months Heterotopic Ossification • Total hip replacement: 20 mg/kg/d for 1 month before surgery and
3 months after surgery • Spinal cord injury: 20 mg/kg/d for 2 weeks followed by 10 mg/kg/d for
_____________________10 weeks_____________________________________________________ Calcitonin-Salmon • 200 lll/d intranasally, alternating nostrils daily
Editors* N otes:
Alendronate sodium is indicated for the prevention of glucocorticoid-induced bone loss. Rapid bone loss occurs after transplantation, placing these patients at increased risk for fractures. Because of improving long-term survival, attention to metabolic bone disease should occur early in the posttransplant course so that the risk o f complications might be lessened.
